Search

Displaying results 3371 - 3380 of 5302 in total
  1. Drug

    Sus scrofa placenta

    go.drugbank.com/drugs/DB14243
    Investigational

    Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Pearl (hyriopsis cumingii)

    go.drugbank.com/drugs/DB14249
    Investigational

    Pearl (hyriopsis cumingii) is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. … Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

  4. Drug

    Streptokinase

    go.drugbank.com/drugs/DB00086
    ApprovedInvestigationalWithdrawn

    Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

  5. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii an...

  6. Drug

    Dental Mesenchymal Pulp Stem Cells

    go.drugbank.com/drugs/DB15737
    Investigational

    They also express specific pluripotency markers like MYC and SOX2 which can be absent in other MSCs. … DPSCs can remain stable in media once extracted, and have a high proliferation and regeneration capacity.

  7. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    Reserpine is derived from Rauwolfia serpentina, and was commonly used as an antihypertensive agent in the 1950s [L1621]. Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097]. … This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630].

  8. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.

  9. Drug

    Revusiran

    go.drugbank.com/drugs/DB16309
    Investigational

    Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy

  10. Drug

    Felzartamab

    go.drugbank.com/drugs/DB16375
    Investigational

    Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).